{"url":"https://newsforagent.com/news/2026-11-20/boston-scientific-prices-senior-notes-penumbra","markdown_url":"https://newsforagent.com/news/2026-11-20/boston-scientific-prices-senior-notes-penumbra.md","title":"Boston Scientific Prices $3 Billion and €4.25 Billion Notes","headline":"Boston Scientific Prices $3 Billion and €4.25 Billion Senior Notes to Fund Penumbra Deal","description":"Boston Scientific priced $3 billion in dollar notes and €4.25 billion in euro notes to fund its Penumbra acquisition, with closing expected December 1.","section":"Funding","published_at":"2026-11-20T02:12:16+00:00","modified_at":"2026-11-20T02:12:16+00:00","author":"News Desk","key_takeaways":["Boston Scientific priced $3 billion of U.S. dollar notes across four series, from 5.375% notes due 2029 to 5.875% notes due 2036.","American Medical Systems Europe B.V. priced €4.25 billion of euro notes in six series, fully guaranteed by Boston Scientific.","Net proceeds will fund the cash consideration for the Penumbra acquisition, with closing expected December 1, 2026."],"companies":[{"name":"Boston Scientific","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00003wf/boston-scientific","website":"http://www.bostonscientific.com"}],"source":{"publisher":"PR Newswire","title":"Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes","url":"https://www.prnewswire.com/news-releases/boston-scientific-announces-pricing-of-3-0-billion-and-4-25-billion-offerings-of-senior-notes-302946308.html"},"other_sources":[],"tags":["Funding","Boston Scientific"],"body_markdown":"Boston Scientific priced $3 billion in U.S. dollar-denominated senior notes and €4.25 billion in euro-denominated notes, the company said in a [PR Newswire](https://www.prnewswire.com/news-releases/boston-scientific-announces-pricing-of-3-0-billion-and-4-25-billion-offerings-of-senior-notes-302946308.html) announcement on November 19, 2026. Proceeds will help fund the cash consideration for its acquisition of Penumbra, Inc.\n\n## Boston Scientific's Four Dollar Note Series\n\nThe [Boston Scientific](https://akta.pro/company-profiles/00003wf/boston-scientific) dollar offering comprises $1 billion of 5.375% senior notes due 2029, $750 million of 5.500% senior notes due 2031, $750 million of 5.750% senior notes due 2033 and $500 million of 5.875% senior notes due 2036. The euro notes were priced by American Medical Systems Europe B.V., the company's indirect wholly owned finance subsidiary, in six series: €500 million of floating rate notes due 2028, €500 million of 3.875% senior notes due 2028, €750 million of 4.125% senior notes due 2030, €750 million of 4.500% senior notes due 2034, €1 billion of 4.750% senior notes due 2038 and €750 million of 5.125% senior notes due 2046. Boston Scientific will fully and unconditionally guarantee the euro notes.\n\nNet proceeds, together with short-term borrowings, borrowings under its credit agreements and cash on hand, will finance the cash consideration payable for Penumbra and related fees and expenses, with any remainder for general corporate purposes. Neither offering is conditioned on the other or on completion of the Penumbra acquisition. If the acquisition is not completed by the applicable special mandatory redemption end date, or the issuer notifies the trustee that it will not pursue the deal, each series except the floating rate notes will be redeemed at 101% of principal plus accrued interest.\n\n## Boston Scientific's Recent Funding Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Boston Scientific's recorded funding includes a $455 million post-IPO equity round in November 2026 led by Blackstone Life Sciences, alongside earlier debt raises.\n\n| Date | Round | Amount |\n| --- | --- | --- |\n| 2026-11 | Post-IPO equity | $455 million |\n| 2025-02 | Post-IPO debt | $1.6 billion |\n| 2024-02 | Post-IPO debt | $2.2 billion |\n| 2022-03 | Post-IPO debt | $3.3 billion |\n\n## Boston Scientific's Path to the Penumbra Financing\n\nIn November 2026, Pomerantz LLP said it was investigating potential securities fraud claims on behalf of Boston Scientific investors, following third-quarter 2026 results that missed estimates and a 5.84% stock drop to $42.43, GlobeNewswire reported. Earlier that month, TradingView reported that Boston Scientific's third-quarter 2026 revenue was $5.14 billion, up 1.4% year over year, while net income fell 22.9% to $582 million, with an August cybersecurity incident disrupting manufacturing, order processing and shipments. In November 2026, Simply Wall St reported that Boston Scientific faced scrutiny after voluntary recalls of Direxion microcatheters and a Nalu Neurostimulation issue, plus lowered guidance.\n\n## Boston Scientific's December 1 Closing Date\n\nBoth offerings are expected to close on December 1, 2026, subject to customary closing conditions, the company said.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}